Haapaniemi group works with optimising genome editing, along with personalised use of targeted therapies in rare diseases. Although the group's research is mainly focused on rare immunodeficiency diseases, the technology can also be used for cancer treatment.
Group leader Emma Haapaniemi is featured in the latest edition of Apollon research magazine (article in Norwegian) about the group's work with CRISPR-Cas9 gene editing technology to develop better targeted therapies for treating rare immune diseases.
In the article Haapaniemi shares different possibilities the group is working on for developing treatments for rare immune diseases. Haapaniemi collaborates with Professor Eivind Valen from the Department of Informatics at the University of Bergen to design how CRISPR technology can be used in the best possible way.
Haapaniemi emphasises the importance of supporting environments that research immunotherapy, so that the individual research groups can complement each other and collaborate in finding solutions to the many challenges. She will join a new Centre of Excellence Precision Immunotherapy Alliance (PRIMA), led by professors Karl-Johan Malmberg and Johanna Olweus, where she will further develop treatments for immunodeficiency diseases and certain forms of cancer.
Apollon is an award winning popular science magazine by the University of Oslo. It aims to highlight the quality and breadth of research activity within the University of Oslo, whilst contributing to an open debate about new research and its findings.